InnoCare Says Orelabrutinib Phase III ITP Study Met Primary Endpoint
InnoCare said its Phase III study of orelabrutinib in immune thrombocytopenia met its primary endpoint.
InnoCare said its Phase III study of orelabrutinib in immune thrombocytopenia met its primary endpoint.